Impact of the spread of COVID-19 on the performance of medical institutions and related businesses
First written in FY2020. 7 of 14 entries say "Mitigated", first in FY2022-Q1. Latest entry: FY2025.
1 other company's latest entry also says "Mitigated".
- FY2025MitigatedAnnual report
「Moves toward the normalization of economic activity accelerated as concern about COVID-19 receded and restrictions on activities were gradually eased, among other factors.」
The impact that COVID-19 had previously had on medical institutions and business performance was described as having eased as concern about the virus receded and restrictions on activities were relaxed. - FY2024-Q2MitigatedAnnual report
「Following the change in the legal classification of COVID-19 under the Infectious Diseases Control Law, revisions were made to subsidies for securing hospital beds for medical institutions and special provisions for medical reimbursement rates.」
The change in COVID-19's legal classification and moves toward the normalization of socioeconomic activity were reported, and the impact of COVID-19 on medical institutions and business performance was described as having eased somewhat from before. Meanwhile, continued responses by the medical care delivery system are required. - FY2024-Q1MitigatedAnnual report
「During the first quarter of the current consolidated fiscal year, Japan's economy showed signs of moving toward the normalization of socioeconomic activity as restrictions on activities related to COVID-19 were eased.」
The easing of restrictions on activities and the change in COVID-19's legal classification were reported, and the impact of COVID-19 on medical institutions and business performance was described as having eased somewhat from the previous period. Meanwhile, the establishment of a high-quality medical care delivery system continues to be required. - FY2023-Q2WorsenedAnnual report
「The medical care delivery system temporarily came under strain due in part to pressure on fever outpatient clinics and an increase in infections among healthcare workers caused by the seventh wave of COVID-19,」
Although the impact had been easing through the previous year, pressure on fever outpatient clinics and an increase in infections among healthcare workers caused by the seventh wave, making the impact on the medical care delivery system concrete again. - FY2023-Q1MitigatedAnnual report
「The number of surgeries was recovering, partly because more people visited medical institutions, but there continued to be a need to establish an efficient, effective and high-quality medical care delivery system capable of responding to COVID-19 and other infections.」
An increase in the number of medical visits and a recovery trend in the number of surgeries were reported, and the impact of COVID-19 on medical institutions and business performance had eased somewhat from the previous year. However, the need to respond to infections remains. - FY2022MitigatedAnnual report
「Although the impact of the infection was easing in the medical industry in which our Group operates, restrictions on medical services continued and some surgeries were postponed, so the provision of routine medical care remained somewhat constrained compared with a typical year.」
Although restrictions on medical visits and surgeries due to COVID-19 remained, the impact of the infection was described as easing, indicating some improvement from the situation through the previous year. - FY2022-Q3WorsenedAnnual report
「The Total Pack Produce business recorded lower profit due to factors including the larger number of smaller project orders than in a typical year, the difficulty in procuring electronic components and resin- and vinyl-based products from manufacturers, which forced the temporary postponement of new contracts, and the impact of a reactionary decline in demand for infection-control products, which also affected the Medical Supply business.」
Although the medical industry as a whole recovered year on year, the reactionary decline in demand for infection-control products emerged as a factor behind lower profit in the Medical Supply business and other operations, while preparations for new variants are also required. - FY2022-Q2MitigatedAnnual report
「Industry conditions recovered compared with the same period last year, mainly due to the rapid decline in new infections as vaccination progressed.」
Although restrictions on medical visits and the impact on the number of surgical cases remained, the medical industry was described as having improved compared with the same period of the previous year, due in part to progress in vaccination. - FY2022-Q1MitigatedAnnual report
「In the medical industry in which the Group operates, patients continued to refrain from seeking medical care and surgical cases continued to decline compared with normal years due to the spread of COVID-19, but conditions improved compared with the same period of the previous year.」
Although patients continued to refrain from seeking medical care and surgical cases continued to decline, the Company explained that conditions had improved compared with the same period of the previous year, indicating that the business risks from COVID-19 had eased to some extent. - FY2021RestatedAnnual report
「The medical industry in which the Group operates has remained in a difficult situation. Particularly at the beginning of the fiscal year, the number of medical institutions experiencing revenue declines due to patients refraining from seeking medical care and a decrease in surgical cases increased as a result of the spread of COVID-19. At the same time, securing personnel, implementing thorough infection-prevention measures and making new investments in equipment have all been required to meet social demands for responses to COVID-19 patients.」
Patients refraining from seeking medical care, a decline in surgical cases and lower medical institution revenue have continued due to COVID-19, along with the burden of investment in infection-control measures and securing personnel. - FY2021-Q3RestatedAnnual report
「The medical industry in which the Group operates has been forced to absorb substantial declines in outpatient and inpatient revenue due to patients refraining from seeking medical care and a decrease in surgical cases caused by the spread of COVID-19. At the same time, social demands for responses to the infection have intensified.」
Patients refraining from seeking medical care, a decline in surgical cases and the resulting impact on medical institution revenue have continued due to COVID-19. The disclosure also notes progress in investment to respond to COVID-19, as well as shortages of specialized medical personnel and the burden of infection-prevention measures. - FY2021-Q2RestatedAnnual report
「The medical industry in which the Group operates has remained in an extremely difficult situation. Particularly at the beginning of the fiscal year, medical institutions were forced to absorb substantial declines in outpatient and inpatient revenue due to patients refraining from seeking medical care and a decrease in the number of surgeries caused by the spread of COVID-19. Subsequently, they have also been required to implement thorough infection-prevention measures and invest in equipment for related countermeasures.」
The Company explained that patients refraining from seeking medical care, a decline in surgical cases, lower outpatient and inpatient revenue, and the burden of investment in infection-control measures have continued due to COVID-19. - FY2021-Q1MaterialisedAnnual report
「At the same time, conventional medical care has also faced difficult circumstances for hospital revenue, including the postponement of non-urgent treatments.」
The spread of COVID-19 resulted in the postponement of non-urgent treatments and patients refraining from seeking medical care. In the dispensing pharmacy business, revenue decreased 1.0% year on year and segment profit decreased 28.5%. - FY2020MaterialisedAnnual report
「The operating environment has become challenging. While there has been special demand supported by government measures for medical facilities, equipment and clinical supplies used to combat infectious diseases, concerns include delayed purchases of medical equipment, a temporary decline in demand for surgical and other clinical supplies, and a decline in the number of prescriptions filled due to a temporary decrease in outpatients.」
The Company stated that the spread of COVID-19 led to patients refraining from seeking outpatient care, a decline in surgical cases, restrictions on hospital admissions and a decrease in the number of prescriptions filled, among other effects, worsening the operating conditions of medical institutions. At the same time, it noted special demand for facilities, equipment and clinical supplies used to combat infectious diseases.